{"id":"NCT01276457","sponsor":"Novartis Pharmaceuticals","briefTitle":"Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients","officialTitle":"An 18 Month Extension to the Multicenter, Randomized, Open-label Trial (NCT00170885) to Evaluate the Safety, Tolerability, and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion, Given According to Different Blood Target Levels, in de Novo Renal Transplant Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2011-01-13","resultsPosted":"2011-04-19","lastUpdate":"2011-05-20"},"enrollment":223,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Transplantation Infection"],"interventions":[{"type":"DRUG","name":"Everolimus 0.25 and 0.75 mg tablets","otherNames":[]},{"type":"DRUG","name":"Cyclosporine very low dose (150-300 ng/mL) microemulsion","otherNames":["Neoral"]},{"type":"DRUG","name":"Cyclosporine low dose (350-500 ng/mL) microemulsion","otherNames":["Neoral"]}],"arms":[{"label":"Upper everolimus blood target + very low dose cyclosporine","type":"EXPERIMENTAL"},{"label":"Standard everolimus blood target + low dose cyclosporine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to allow the continuation of everolimus treatment in patients who have completed the core study (NCT00170885) and to collect long-term safety, tolerability, and efficacy data in a group of patients treated with the upper everolimus target levels plus very low dose cyclosporin in comparison with the standard everolimus target levels plus low dose cyclosporin in patients with renal transplantation.","primaryOutcome":{"measure":"Number of Participants With Biopsy-proven Acute Rejection","timeFrame":"Baseline to end of study (Month 24)","effectByArm":[{"arm":"Upper Everolimus Blood Target + Very Low Dose Cyclosporine","deltaMin":21,"sd":null},{"arm":"Standard Everolimus Blood Target + Low Dose Cyclosporine","deltaMin":21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":85,"n":142},"commonTop":["Anaemia","Urinary tract infection","Dyslipidaemia","Oedema peripheral","Pyrexia"]}}